Searched for
CUSTOM SYNTHESIS
Anupam Rasayan completes Bliss GVS deal, targets Rs 4,000-crore integrated platformAnupam Rasayan India Limited has finalised its acquisition of a controlling interest in Bliss GVS Pharma, marking a strategic expansion int...- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsThe next time you take some action in the stock market – whether it is buying or selling – ask yourself these questions: Why am I doing thi...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsThere are times when a watchlist is more important than a buy list. But if you still insist on putting money in the market, look at fundame...
- Coal India Limited announces ambitious Business Development portfolio for diversification beyond miningCoal India Limited announced its ambitious business development portfolio on Sunday. This plan focuses on five key platforms for future exp...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsAs an investor, what you need to do at this point of time is this: A bit of extra work in terms of stock-picking so that you avoid anxiety ...
- Banned beauty products are still one click away in India and around the worldBanned skin-bleaching products containing mercury are still available for purchase online. These illegal items are found on Amazon, Temu, a...
- “Whether we leave anyone behind”: Sameer Nigam’s blueprint for PhonePe’s second decadeAt Global Fintech Fest 2026, PhonePe founder‑CEO Sameer Nigam framed the company’s first ten years as the construction of India’s financial...
- PhonePe's Sameer Nigam unveils vision for next decade of financial inclusion at GFF 2026PhonePe has shared its ambitious ten-year strategy aimed at transforming India's digital landscape and promoting financial inclusion. By el...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsIn the equity market, it is generally good to keep one eye on risk management. But there are times when it becomes a must-do. We are curren...
- Chemical sector: Although long, there is a way around China trouble; combine 20 stocks to get your portfolio’s chemistry rightFor the chemicals sector, it all depends on a transformation that is still unfolding and will take years to play out. Backward-integration ...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- Famous Japanese proverb of the day: "Cold and heat last until the equinox" — Inspiring life lessons on patience, resilience, hope, perseverance, emotional strength, personal growth, and why every difficult season eventually gives way to brighter days through timeless Japanese wisdomJapanese proverb of the day: The Japanese proverb "Cold and heat last until the equinox" (Atsusa samusa mo higan made) offers a powerful, n...
- Domestic formulations, chronic therapies to drive Pharma Q1; US generics remain dragThe healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...
- Divi's Labs Q3 net profit zooms 66% to Rs 594 croreDivi's Laboratories on Monday reported a 66% year-on-year (YoY) jump in net profit to Rs 594 crore for the quarter ended December 31, 2024 ...
- Divi’s Laboratories Q2 Results: Company posts 47% jump in net profit in Q2FY25Divi's Laboratories witnessed a 46.6% surge in profit, reaching Rs. 510 crores in Q2FY25, fueled by robust growth in their custom synthesis...
- JetSynthesys signs pact with Japan’s Digital Hearts HoldingsAs part of this collaboration, the company said DHH will invest in JetSynthesys Japan while JetSynthesys Japan will harness DHH's expertise...
- Pharma can give PI Industries the growth booster it needsDespite hindrances, the stock has delivered a tremendous CAGR of 43, 25 and 37 per cent in 3, 5 and 10 years, respectively. This makes PI a...
- Up 670% in 4 years, this API maker’s adrenaline rush is simply not endingThe stock escaped the broader selloff of March 2020 and remained unfazed in the face of the Covid 2.0 volatility, as it kept on hitting rec...
- Citi initiates coverage on PI Industries with ‘buy’Citi said the strong order book of $850 million of PI Industries’ custom synthesis and manufacturing business adds a clear revenue visibili...
- PI Industries aims to double turnover to Rs 1,750 cr by FY 15In the agro-chemicals market, which is worth Rs 12,000 to 13,000 crore, PI Industries in among the top five players.
Load More
